Insider · CIK 0001910456
Lynx1 Capital Management LP
Files at TCRX (TScan Therapeutics, Inc.), PASG (Passage BIO, Inc.). First filing Nov 19, 2024, latest May 21, 2025.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
TCRX: TScan Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
PASG: Passage BIO, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | TCRXbuy TScan Therapeutics, Inc. | $3.1M 2,588,794 shares | +48% | +13% from low-79% from high | |
| 25Weak | PASGbuy Passage BIO, Inc. | $241k 373,645 shares | +4% | - | |
| 28Weak | TCRXbuy TScan Therapeutics, Inc. | $386k 131,800 shares | +3% | - | |
| 24Weak | PASGbuy Passage BIO, Inc. | $285k 456,353 shares | +5% | - | |
| 2Weak | TCRXbuy TScan Therapeutics, Inc. | $4,114 947 shares | +0% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 19, 2025 | TCRX TScan Therapeutics, Inc. | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +1,388,794 | $1.20 | $1.7M | 6,746,141 | May 21, 2025 |
| May 20, 2025 | TCRX TScan Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +1,200,000 | $1.20 | $1.4M | 7,946,141 | May 21, 2025 |
| Dec 27, 2024 | PASG Passage BIO, Inc. | POpen-market purchase Common stock, $0.0001 par value per shareindirect: See footnote | +373,645 | $0.65 | $241k | 9,256,953 | Dec 31, 2024 |
| Dec 26, 2024 | TCRX TScan Therapeutics, Inc. | POpen-market purchase Pre-funded Warrant (right to buy)derivativeindirect: See footnote | +7,500,000 | $4.00 | $30M | 7,500,000 | Dec 30, 2024 |
| Dec 12, 2024 | TCRX TScan Therapeutics, Inc. | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +31,800 | $3.01 | $96k | 5,257,347 | Dec 16, 2024 |
| Dec 13, 2024 | TCRX TScan Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See footnote | +100,000 | $2.90 | $290k | 5,357,347 | Dec 16, 2024 |
| Nov 25, 2024 | PASG Passage BIO, Inc. | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +259,998 | $0.56 | $147k | 8,686,953 | Nov 27, 2024 |
| Nov 26, 2024 | PASG Passage BIO, Inc. | POpen-market purchase Common Stockindirect: See footnote | +167,055 | $0.71 | $118k | 8,854,008 | Nov 27, 2024 |
| Nov 27, 2024 | PASG Passage BIO, Inc. | POpen-market purchase Common Stockindirect: See footnote | +29,300 | $0.67 | $20k | 8,883,308 | Nov 27, 2024 |
| Nov 15, 2024 | TCRX TScan Therapeutics, Inc. | POpen-market purchase Common stock, $0.0001 par value per shareindirect: See footnote | +947 | $4.34 | $4,114 | 5,225,547 | Nov 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.